GE HealthCare (GEHC) is reporting revenue growth for its 2025 fourth quarter and full fiscal year.
The company posted revenues of $5.7 billion for the fourth quarter, up 7.1% over the same period last year, driven by its Pharmaceutical Diagnostics (PDx), Imaging, and Advanced Visualization Solutions (AVS) segments, the company said. PDx revenues jumped 22.3% to $790 million, up from $646 in the fourth quarter last year, while Imaging revenues rose 6.6% to $2.55 billion, and AVS revenues rose 5.9% to $1.52 billion, GEHC said.
Meanwhile, net income dropped to $589 million versus $720 million in the fourth quarter last year. This represents a net income margin of 10.3% versus 13.5% year-over-year, with income negatively impacted by tariff expense and unfavorable mix, the company noted.
For the full year, GEHC posted total revenues of $20.6 billion, up 4.8% from $19.6 in 2024, with total orders up 5.2% organically. The company said its net income for 2025 was flat compared to 2024, at $2.1 billion versus $2 billion.
“We ended 2025 in a position of strength with record backlog. We significantly mitigated gross tariff impacts, demonstrating operational resilience,” said GEHC Vice President and Chief Financial Officer Jay Saccaro in a statement.
GEHC noted that it expects tariff impacts to be lower in 2026 than in 2025, based on current rates.
